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Objective: Recently, acquired as well as genetic prothrombotic factors are
associated with thrombotic events. These factors have also been related to
conditions of uteroplacental insufficiency such as pre-eclampsia, HELLP syndrome
and severe intrauterine growth restriction (IUGR). The aim of this study was to
determine whether elevated factor VIII levels are associated with uteroplacental
insufficiency, in particular pre-eclampsia, HELLP syndrome or pregnancy-induced
hypertension and intrauterine growth retardation.
Methods: Plasma samples of 75 women with a history of pregnancy complicated by
pre-eclampsia, HELLP syndrome, pregnancy induced hypertension or intrauterine
growth restriction were tested for factor VIII:C (FVIII:C) levels at a minimum of 10
weeks post-partum. Laboratory results were compared to factor VIII:C levels found
in a healthy control group of 272 women.
Results: Mean factor VIII:C levels were similar at 123 IU/dl in both the patient group
and the controls. In a logistic regression model, after adjusting for age and blood
group, no effect of factor VIII:C levels on the risk of pregnancy complications was
observed, with the exception of IUGR with (OR 2.9, CI 1.0—8.7) or without
hypertension (OR 2.0, CI 0.7—6.4).
Conclusion: If the elevated level of factor VIII would be the sole factor responsible
for the increased risk observed, one would expect to find an effect of blood group onThrombosis Research (2005) 115, 387—3924 Elsevier Ltd. All rights reserved.
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C.P.J. Witsenburg et al.388risk as well (blood group being an important determinant of FVIII:C). While no such
effect could be shown a causal relationship between elevated levels of factor VIII
and conditions of uteroplacental insufficiency such as pre-eclampsia, HELLP
syndrome, pregnancy-induced hypertension and IUGR is not very likely.
D 2004 Elsevier Ltd. All rights reserved.Introduction
Approximately 1—5% of all pregnancies are com-
plicated by serious conditions such as pre-eclamp-
sia, HELLP syndrome (haemolysis, elevated liver
enzymes and low platelets), solutio placentae,
severe intrauterine growth restriction (IUGR),
foetal loss and stillbirth [1]. In general, these
conditions are thought to be related to a poor
trophoblastic invasion of maternal spiral arteries,
leading to a syndrome known as uteroplacental
insufficiency. The mechanisms of uteroplacental
insufficiency are largely unknown and its aetiology
is likely to be multicausal: immunological as well
as genetic factors may be involved, which may
include factors involved in blood clotting [2—5].
Recently, insights in the causes of thrombosis
have grown, which include genetic as well as
acquired risk factors such as deficiencies of anti-
thrombin, protein C and protein S, activated protein
C resistance due to the factor V Leidenmutation and
prothrombin G20210A mutation. High levels of
procoagulant factors, such as factor VIII, factor IX
and factor XI, have also been associated with an
increased risk of venous thrombosis [6—11], as has
hyperhomocysteinaemia [12—14]. Only recently,
these factors have been related to uteroplacental
insufficiency. Thrombophilic defects, notably defi-
ciencies of anticoagulant factors, were found in up
to 50% of patients with severe pre-eclampsia and
HELLP syndrome [3] and they have been associated
with an increased risk of stillbirth as well as foetal
growth retardation [15,16].
Elevated levels of factor VIII:C (FVIII:C) are a
common risk factor for venous thrombosis [17—
19]. They may also be associated with an
increased risk of arterial thrombosis in coronary
heart disease [20,21]. The basis of high levels of
FVIII is unclear: it is partly associated with ABO
blood group (lower levels in type O) and APC
resistance, but additional variation in FVIII levels
has been shown to cluster in families too [22].
When a cut-off point for high levels of 150 IU/dl is
used the prevalence of elevated FVIII:C is high:
11% of healthy control subjects and 25% of
patients with a first episode of deep-vein throm-
bosis were found to have FVIII:C levels N150 IU/dl
[23]. Factor VIII in plasma is bound to vonWillebrand factor (VWF) and its levels are to a
large degree determined by the levels of VWF,
which on its turn are dependent on blood group
[24,25]. Elevated levels of FVIII:C in patients with
venous thromboembolism have been shown to
persist over time [17,31] and independent of
acute-phase reactions [17,19,32].
In the 1970s and 1980s, several authors reported
an elevated ratio of VWF/FVIII:C during pregnancy
and an even higher ratio in pregnancies compli-
cated by pre-eclampsia [26—29] and hypertension
[30,31]. Altered coagulation status due to these
conditions might increase the factor VIII:C con-
sumption, causing plasma FVIII:C levels to go down.
Elevated levels of VWF, which is known to increase
in diseases associated with endothelial activation,
might add to this effect.
In this study, we set out to determine whether
persistent elevated factor VIII:C levels were asso-
ciated with conditions of uteroplacental insuffi-
ciency in a group of 75 women with a history of
pregnancy complicated by hypertensive disorders
(pre-eclampsia, HELLP syndrome or pregnancy-
induced hypertension) or intrauterine growth
restriction.Methods
Patients and study design
Women reporting to our clinic with a history of
hypertensive complications or IUGR during a pre-
ceding pregnancy are screened for the presence of
thrombophilic defects, among which factor VIII:C.
Between august 1999 and July 2002 FVIII:C levels
were determined in a group of 75 women with one
of these complications in their index pregnancy.
Plasma FVIII:C levels were measured at a minimum
of 10 weeks post-partum, patients using oral
contraceptives at the time of testing being
excluded. With regard to the different complica-
tions of pregnancy 20 of the women had a history of
IUGR only, 36 had suffered from hypertensive
disorders during pregnancy and 19 women had
had a combination of the 2. Laboratory results
were compared to factor VIII:C levels found in 272
Table 1 Mean FVIII:C levels in patients with a history of pre-eclampsia, HELLP syndrome, pregnancy-induced
hypertension and/or IUGR and healthy controls
Blood type O Blood type non-O Total
N Mean 95% CI N Mean 95% CI N Mean 95% CI
Patients
PE/HELLP/HT+IUGR (n=19) 5 121 82—159 14 146 121—173 19 140 119—161
IUGR (n=20) 9 113 83—143 11 129 98—159 20 122 102—141
PE/HELLP/HT (n=36) 11 120 84—156 25 111 94—129 36 114 99—129
Total 25 118 100—135 50 125 112—138 75 123 112—133
Controls 111 110 104—117 161 132 128—137 272 123 120—127
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Thrombophilia Study (LETS) [18].
Definitions
Pre-eclampsia was defined as pregnancy-induced
hypertension (diastolic blood pressure z90 mm Hg)
plus significant proteinuria (urinary protein excre-
tion N300 mg/24 h or two 2+ or higher readings of on
dipstick analysis of midstream or catheter urine
samples) after 20 weeks of gestational age. Eclamp-
sia was defined as the occurrence of generalised
convulsions during pregnancy, during labour or
within 7 days of delivery, not caused by epilepsy or
other convulsive disorders. HELLP syndrome was
defined as the presence of haemolysis (LDHN600 IU/
l), elevated liver enzymes (SGOTN70 IU/l) and
thrombocytopenia (b100.109/l) [33]. Intrauterine
growth restriction finally was defined as a neonatal
birth weight below the 10th percentile, while
individuals with other causes such as gross chromo-
somal disorders and viral infections were excluded
[34].
Laboratory tests
Venous blood samples were taken from the subjects
at a minimum of 10 weeks post-partum in 106
mmol/l trisodium citrate. Factor VIII:C levels were
determined by a one-stage clotting assay [18].Table 2 Mean differences between patients and controls
Blood type O Blood ty
n Mean
difference
95% CI n Me
dif
PE/HELLP/HT+IUGR
(n=19)
5 0.15 0.25 to 0.54 14 0
IUGR (n=20) 9 0.11 0.18 to 0.41 11 0
PE/HELLP/HT
(n=36)
11 0.19 0.17 to 0.54 25 0
Total 25 0.15 0.03 to 0.33 50 0Statistical analysis
The analysis was performed by comparing FVIII:C
levels in 75 patients and 272 female population
controls. First, we compared mean levels of FVIII:C
between cases and controls, with 95% confidence
interval for the difference of the means. Subse-
quently, we calculated odds ratios as a measure for
the relative risk, by cross-tabulation and logistic
regression for various cut-off values. Odds ratios
(and 95% confidence intervals) adjusted for blood
type and age were derived from the model.Results
We included 75 patients and 272 controls. Patients
had a history of IUGR (n=20), pre-eclampsia, HELLP
syndrome or pregnancy induced hypertension
(n=36), or a combination of the 2 (n=19). Median
age of the patients at the time of the blood draw
was 31.6 (range 23.8—44.4 years), while for the
controls it was 44.8 years (range 17—72).
In both the patient and control group, mean
levels of factor VIII:C were 123 IU/dl. Blood group 0
was present in 25 (33%) of the patients and 111
(41%) of the control women. When we stratified the
patients by ABO blood group, mean FVIII:C levels
were 118 IU/dl for blood type O (n=25) and 125 IU/
dl for blood type non-O (n=50). In the controlin FVIII:C concentration
pe non-O Total
an
ference
95% CI n Mean
difference
95% CI
.03 0.23 to 0.29 19 0.06 0.14 to 0.26
.16 0.46 to 0.15 20 0.04 0.23 to 0.17
.31 0.50 to 0.12 36 0.16 0.33 to 0.02
.18 0.31 to 0.05 75 0.07 018 to 0.04
Table 3 Odds ratio (and 95% confidence intervals) in
patients with a raised FVIII:C levels (above 150 IU/l)
compared to controls
Raised FVIII levels
Blood type O Blood type
non-O
Incidence OR
(95% CI)
Incidence OR
(95% CI)
PE/HELLP/
HT+IUGR
20% 1.9
(0.2—18.2)
43% 2.4
(0.8—7.2)
IUGR 11% 0.9
(0.1—8.2)
36% 1.8
(0.5—6.4)
PE/HELLP/
HT
27% 2.8
(0.7—12.0)
16% 0.6
(0.2—1.8)
Controls 12% 24%
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blood type O (n=111) and 132 IU/dl for non-O
(n=161). We also calculated mean factor VIII:C
levels for the different complications of pregnancy.
Factor VIII levels seemed to be the highest in
patients with a history of combined IUGR/hyper-
tensive disorders, the lowest in patients with
hypertensive disorders only, and intermediate in
patients with IUGR only, although confidence
intervals were wide (Table 1).
Mean differences between patients and controls
stratified for blood group type are given in Table 2.
We only found a difference in factor VIII:C levels in
patients with a non-O blood group, particularly in
the group of hypertensive patients without foetal
growth restriction.
The risk associated with high factor VIII:C levels
was estimated stratified for blood group type for
each of the pregnancy complications separately, by
using factor VIII:C levels of 150 IU/l as a cut-off
value. Odds ratios and confidence intervals are given
in Table 3. In this comparison to controls, no specific
relation is seen between raised FVIII:C levels (N150
IU/l) and the different pregnancy complications for
both O and non-O blood group type.
In a multivariate logistic regression model, we
assessed the contribution to risk, for each of the
complications, of blood group and elevated factorTable 4 Odds ratio (and 95% confidence intervals) in p
compared to controls
Blood group
(unadjusted)
Blood group
(adjusted for FVIII)
PE/HELLP/
HT+IUGR
0.5 (0.2—1.5) 0.6 (0.2—1.9)
IUGR 1.1 (0.4—2.8) 1.2 (0.4—3.3)
PE/HELLP/
HT-IUGR
0.7 (0.3—1.4) 0.7 (0.3—1.5)
Total 0.7 (0.4—1.3) 0.8 (0.4—1.4)VIII levels, adjusted for age. FVIII:C appeared to
increase risk with factor three for hypertensive
complications in combination with IUGR (adjusted
OR 2.9, CI 1.0—8.7). For IUGR without hypertensive
complications, a two-fold increased risk was found
(adjusted OR 2.0, CI 0.7—6.3). For hypertensive
complications without IUGR, no effect on risk of
FVIII:C levels was observed (adjusted OR 1.2, CI
0.5—3.2) (Table 4).Discussion
Given the recently reported association between
elevated FVIII levels and thrombotic events, one
might expect to find a similar association with
regard to pregnancy complications. It was shown
that a raised F VIII level is an independent risk
factor for early recurrent miscarriage [35]. Other
studies have found a raised VWF:Ag/FVIII:C ratio in
hypertensive pregnant women [30,31]. This might
be caused by either a raised VWF:Ag or a decreased
FVIII level. The first suggestion is supported by
studies in hypertensive-preeclamptic pregnant
women where indeed a raised VWF:Ag level is
found [36,37]. In our study, which concentrated on
absolute FVIII:C levels, no clear association
between FVIII:C levels postpartum and the risk of
hypertensive pregnancy complications could be
demonstrated. In the subgroup of patients with a
history of IUGR with (OR 2.9, CI 1.0—8.7) or without
hypertension (OR 2.0, CI 0.7—6.4), we found that
raised FVIII:C levels were related to mildly elevated
odds ratios with broad confidence intervals.
Mean factor VIII:C levels in the patient group and
in the control group were not different. Stratifica-
tion by ABO blood group led to similar results. For
the different complications of pregnancy, FVIII
levels were higher in patients with a history of a
combined IUGR/hypertensive disorder, lower in
patients with hypertensive disorders only and
intermediate in patients with IUGR only, but the
wide confidence intervals did not allow a firm
conclusion.atients with a raised FVIII:C levels (above 150 IU/l)
High FVIII:C
(unadjusted)
High FVIII:C
(adjusted for blood group)
3.2 (1.1—9.4) 2.9 (1.0—8.7)
2.0 (0.6—6.0) 2.0 (0.7—6.4)
1.3 (0.5—3.4) 1.2 (0.5—3.2)
1.8 (0.9—3.6) 1.7 (0.9—3.5)
Factor VIII levels 391Clinical manifestations of uteroplacental insuffi-
ciency in the mother disappear very shortly after
birth. As FVIII:C levels were measured at a mini-
mum of 10 weeks post-partum, it seems unlikely
that factor VIII levels were by then still influenced
as a result of these conditions. Blood group is an
important determining factor in FVIII levels. There-
fore, in case elevated FVIII:C was to increase the
risk of these complications of pregnancy, one would
expect to find an increased risk of non-O blood
group on pregnancy complications as well. How-
ever, we did not find any effect of blood group, also
after correction for FVIII levels, on the risk for one
of the studied complications of pregnancy. This
makes a causal relation between FVIII and utero-
placental insufficiency less likely.
In the multivariate logistic regression model,
elevated factor VIII levels were associated with a
two- to three-fold increased risk of IUGR. Again,
the sample size precludes definite conclusions, but
one is tempted to speculate that elevated levels of
FVIII have a common background with the causes of
placental insufficiency. In general, these conditions
are thought to be related to a poor trophoblastic
invasion of maternal spiral arteries. The mecha-
nisms of uteroplacental insufficiency are largely
unknown, but factors involved in blood clotting
might well contribute to its aetiology [2—5].
Previous studies have shown an increased risk of
pre-eclampsia in women with a low APC-sensitivity
ratio, i.e., some form of APC-resistance, in the
absence of factor V Leiden [22]. It is also known
that factor VIII levels and APC-sensitivity ratios are
inversely related, i.e., high factor VIII levels are
associated with APC-resistance. It is likely that this
represents increased thrombin generation, but,
since we observed no effect from ABO-blood group,
that this is acquired rather than genetically
determined.References
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